Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants

Summary

Oxidative modification of LDL, which dysregulates the homeostasis between blood and vascular cells, and alterations of endothelial function are considered among the early events in the pathogenesis of atherosclerosis. This study was designed to evaluate the impact of progressive LDL oxidation on the thrombotic response both in vitro and in vivo, and to address the potential effect of antioxidants. Tissue factor was induced by progressive LDL oxidation in HUVEC, and this event was in parallel to the appearance of the apoptotic phenotype. Both these phenomena were mediated by ERK1/2 activation and were prevented by LDL pre-enrichment with antioxidants. In contrast, antioxidants failed to affect tPA and PAI-1 secretion, which was increased by LDL, either native or oxidized. Tissue factor-pathway inhibitor was also increased upon HUVEC exposure to progressively oxidized LDL. LDL, in the presence of an oxidative agent, trigger a thrombogenic response in vivo, mostly TF-dependent, in an in situ model of platelet deposition. This effect was markedly attenuated when LDL were enriched with antioxidants. It can be concluded that vascular thrombogenicity is induced by progressive LDL oxidation and that alterations of the antioxidant/oxidant balance of the LDL particle in favor of the antioxidant tone are protective against the thrombotic response triggered by oxidative stress. The extrapolation of these data in a clinical setting, even if not easy, offers potential insights for the use of antioxidants in the prevention of thrombotic complications associated with atherothrombosis.

Keywords

Endothelial cells - LDL oxidation - thrombosis - fibrinolysis - antioxidants

• References

• 1 Chisolm GM, Penn MS. Oxidized lipoproteins and atherosclerosis. In: Atherosclerosis and Coronary Artery Disease. Fuster V, Ross R, Topol EJ, eds. Philadelphia, Pa: Lippincott-Raven 1996; 129-49.
• 2 Ehara S, Ueda M, Naruko T. et al Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-60.
• 3 Toshima S, Hasegawa A, Kurabayashi M. et al Circulating oxidized low density lipo-protein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2243-7.
• 4 Yla-Herttuala S, Palinski W, Rosenfeld ME. et al Evidence for the presence of oxidatively modified low density lipoprotein in athero-sclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
• 5 Cines DB, Pollak ES, Buck CA. et al Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
• 6 Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
• 7 Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: clinical significance and therapeutic intervention. Thromb Haemost 1997; 78: 247-55.
• 8 Tremoli E, Camera M, Toschi V, Colli S. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
• 9 Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991; 138: 601-7.
• 10 Penn MS, Cui MZ, Winokur AL. et al Smooth muscle cell surface tissue factor pathway activation by oxidized low-density lipoprotein requires cellular lipid peroxidation. Blood 2000; 96: 3056-63.
• 11 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
• 12 Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999; 82: 259-70.
• 13 Arnman V, Nilsson A, Stemme S, Risberg B, Rymo L. Expression of plasminogen activator inhibitor-1 mRNA in healthy, atherosclerotic and thrombotic human arteries and veins. Thromb Res 1994; 76: 487-99.
• 14 Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-801.
• 15 Tremoli E, Camera M, Maderna P. et al Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. Arterioscler Thromb 1993; 13: 338-46.
• 16 Kugiyama K, Sakamoto T, Misumi I. et al Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993; 73: 335-43.
• 17 Chautan M, Latron Y, Anfosso F. et al Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res 1993; 34: 101-10.
• 18 Rimm EB, Stampfer MJ, Ascherio A. et al Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
• 19 Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123: 860-72.
• 20 MRC/BHF Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-33.
• 21 Praticò D, Tangirala RK, Rader DJ. et al Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998; 4: 1189-92.
• 22 Iuliano L, Mauriello A, Sbarigia E, Spagnoli LG, Violi F. Radiolabeled native low-density lipoprotein injected into patients with carotid stenosis accumulates in macrophages of atherosclerotic plaque: effect of vitamin E supplementation. Circulation 2000; 101: 1249-54.
• 23 Saldeen T, Li D, Mehta JL. Differential effects of alpha-and gamma-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogene-sis. J Am Coll Cardiol 1999; 34: 1208-15.
• 24 Dichtl W, Stiko A, Eriksson P. et al Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 3025-32.
• 25 Eligini S, Banfi C, Brambilla M. et al 15-Deoxy-Δ^12,14-prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: evidence for ERK1/2 signaling pathway blockade. Thromb Haemost 2002; 88: 524-32. .
• 26 Bergamaschi D, Ronzoni S, Taverna S. et al Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound. Br J Cancer 1999; 79: 267-77.
• 27 Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 1986; 6: 312-20.
• 28 Camera M, Toschi V, Comparato C. et al Cholesterol-induced thrombogenicity of the vessel wall: inhibitory effect of fluvastatin. Thromb Haemost 2002; 87: 748-55.
• 29 Locher R, Brandes RP, Vetter W, Barton M. Native LDL induces proliferation of human vascular smooth muscle cells via redox-mediated activation of ERK 1/2 mitogen-activated protein kinases. Hypertension 2002; 39: 645-50.
• 30 Go YM, Levonen AL, Moellering D. et al Endothelial NOS-dependent activation of c-Jun NH(2)-terminal kinase by oxidized low-density lipoprotein. Am J Physiol Heart Circ Physiol 2001; 281: H2705-13.
• 31 Horie S, Hiraishi S, Hamuro T, Kamikubo Y, Matsuda J. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein. Thromb Haemost 2002; 87: 80-5.
• 32 Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 2002; 105: 2030-6.
• 33 Gorlach A, Brandes RP, Bassus S. et al Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J 2000; 14: 1518-28.
• 34 Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000; 87: 179-83.
• 35 Leonarduzzi G, Arkan MC, Basaga H. et al Lipid oxidation products in cell signaling. Free Radic Biol Med 2000; 28: 1370-8.
• 36 Ushio-Fukai M, Alexander RW, Akers M, Griendling KK. p38 mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II: role in vascular smooth muscle cell hypertrophy. J Biol Chem 1998; 273: 15022-29.
• 37 Bhunia AK, Han H, Snowden A, Chatterjee S. Redox-regulated signaling by lactosylceramide in the proliferation of human aortic smooth muscle cells. J Biol Chem 1997; 272: 15642-9.
• 38 Rao GN, Alexander RW, Runge MS. Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 1995; 96: 842-7.
• 39 Mechtcheriakova D, Schabbauer G, Lucerna M. et al Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001; 15: 230-42.
• 40 Salomonsson L, Pettersson S, Englund MC, Wiklund O, Ohlsson BG. Post-transcriptional regulation of VEGF expression by oxidised LDL in human macrophages. Eur J Clin Invest 2002; 32: 767-74.
• 41 Jing Q, Xin SM, Cheng ZJ. et al Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: mediation via pertussis toxin-sensitive G proteins and association with oxidized LDL-induced cytotoxicity. Circ Res 1999; 84: 831-9.
• 42 Greeno EW, Bach RR, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest 1996; 75: 281-9.
• 43 Mallat Z, Hugel B, Ohan J. et al Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-53.
• 44 Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270: 1326-31.
• 45 Gupta K, Kshirsagar S, Li W. et al VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 1999; 247: 495-504.
• 46 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
• 47 Brisseau GF, Dackiw AP, Cheung PY, Christie N, Rotstein OD. Posttranscriptional regulation of macrophage tissue factor expression by antioxidants. Blood 1995; 85: 1025-35.
• 48 Li JM, Mullen AM, Yun S, Wientjes F, Brouns GY, Thrasher AJ, Shah AM. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res 2002; 90: 143-50.
• 49 Ferro D, Basili S, Pratico D, Iuliano L, FitzGerald GA, Violi F. Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. Blood 1999; 93: 2945-50.
• 50 Pratico D, Ferro D, Iuliano L. et al Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. Blood 1999; 93: 3401-7.
• 51 Ren S, Shen GX. Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 1688-93.
• 52 Rifici VA, Schneider SH, Chen Y, Khachadurian AK. Administration of antioxidant vitamins does not alter plasma fibrinolytic activity in subjects with central obesity. Thromb Haemost 1997; 78: 1111-4.
• 53 Bonfigli AR, Pieri C, Manfrini S, Testa I, Sirolla C, Ricciotti R, Marra M, Compagnucci P, Testa R. Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients. Diabetes Nutr Metab 2001; 14: 71-7.
• 54 Ishii H, Kizaki K, Horie S, Kazama M. Oxidized low density lipoprotein reduces thrombomodulin transcription in cultured human endothelial cells through degradation of the lipoprotein in lysosomes. J Biol Chem 1996; 271: 8458-65.
• 55 Horie S, Hiraishi S, Hirata Y, Kazama M, Matsuda J. Oxidized low-density lipoprotein impairs the anticoagulant function of tissue-factor-pathway inhibitor through oxidative modification by its high association and accelerated degradation in cultured human endothelial cells. Biochem J 2000; 352: 277-85.
• 56 Zieseniss S, Zahler S, Muller I, Hermetter A, Engelmann B. Modified phosphatidylethanolamine as the active component of oxidized low density lipoprotein promoting platelet prothrombinase activity. J Biol Chem 2001; 276: 19828-35.
• 57 Volf I, Roth A, Moeslinger T. et al Stimulating effect of biologically modified low density lipoproteins on ADP-induced aggregation of washed platelets persists in absence of specific binding. Thromb Res 2000; 97: 441-9.
• 58 Pawlowska Z, Swiatkowska M, Krzeslowska J, Pawlicki L, Cierniewski CS. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis 1993; 103: 13-20.
• 59 Violi F, Micheletta F, Iuliano L. Vitamin E, atherosclerosis and thrombosis. Thromb Haemost 2001; 85: 766-70.